H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Kymera Therapeutics to $46 from $30 and keeps a Buy rating on the shares. The analyst says the company’s Tyk-2 program is differentiated by its power to impact the scaffolding function. KT-294 differentiates from deucravacitinib by completely blocking Type I IFN but leaves out IL-10/22, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KYMR:
- Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
- Kymera Therapeutics initiated with a Peer Perform at Wolfe Research
- Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
- Kymera Therapeutics provides 2024 corporate goals
